Thermogenesis: Der neue Biotech Star - 500 Beiträge pro Seite

[Stock@dvisor]

Auf dem akt Niveau (4 €) ist diese Aktie sicherlich ein excellenter Kauf. Die heftigen Kursausschläge heute morgen waren sicherlich übertrieben. Mittelfristig sehe ich aber durchaus Kurse im zweistelligen Bereich.

Es spricht schon für sich, wenn DER Kenner der Biotech-Branche Bruno Wagner diesen Wert empfiehlt.
Sein Buch wird jedenfalls sehr gelobt:

http://www.amazon.de/exec/obidos/ASIN/3706406470/o/qid=96816…

Schaut Euch mal die Homepage von Thermogenesis an: http://www.thermogenesis.com/

Die Marktkapitalisierung liegt bei 66 Millionen $. Eigentlich ein Witz, wenn man sieht wie hoch vergleichbare Unternehmen gehandelt werden.
Bisher war KOOL (so das NASDAQ-Kürzel) noch so etwas wie eine unentdeckte Perle. Dies scheint mit dem heutigen Tag vorbei zu sein.

Selbst diejenigen, die heute Kurse über 5€ gezahlt haben, dürften sich bald nicht mehr über diesen "NTV-Aufschlag" grämen.

[Plato]

THERMOGENESIS Corp. designs, develops, manufactures, and sells products
and devices that utilize its proprietary thermodynamic technology for the
processing of biological substances including the cryopreservation, thawing, and
harvesting of blood components. The Company was incorporated July 1986 as
InstaCool, Inc. of North America, and subsequently merged with Refrigeration
Systems International, Inc. In January of 1995, the Company changed its name to
the present to better reflect the thermodynamic blood-processing segment of the
biotechnology industry that it hopes to service through development of new
products.

Historically, THERMOGENESIS` primary revenues were from sales of ultra rapid
blood plasma freezers and thawers to hospitals, blood banks and blood transfusion
centers and plasma collection centers under US Food & Drug Administration
(FDA) clearance to market in the United States. During the fiscal years 1988
through 1995, the Company focused research and development efforts on the
refinement of product design for its blood plasma freezers and thawers. During that
period, the Company also sought new applications for its technology, including the
design of micro-manufacturing systems for biopharmaceutical drugs that utilize the
Company`s thermodynamic competence in new medical therapies.

Ultra Rapid Heat Freezers and Thawers

The Company`s Ultra Rapid freezers and thawers use heat transfer liquids, rather
than gases such as air, carbon dioxide or nitrogen to transfer heat to and from a
biological substance. The Company`s patented thin flexible plastic membrane
system is automatically interposed between the heat transfer liquid and the
container housing the blood component. Tests of the technology performed by the
Hague Center of the Netherlands Red Cross reports that 300 ml bags of plasma
were core frozen in 30 minutes versus 90-120 minutes in air blast freezers that
resulted in 18 to 32% more factor VIII in the cryoprecipitate from the frozen plasma.

In late Fiscal Year 1999, MP1100 MicroCascade, the first major upgrade of the
plasma freezer line was introduced. The MicroCascade is a breakthrough new
refrigeration technology that provides radically accelerated freezing performance.
The small, lightweight (100 lbs) integrated MicroCascade compressor/condenser
utilizing compact, lightweight Schroll compressors provides refrigeration capacity
equivalent to a bulky, heavy 8hp conventional remote compressor/condenser. The
advantage of the MicroCascade technology is that expensive and inflexible remote
condenser installations are not required. This flexibility allows laboratories to
quickly start up or modify their production routing by rolling in the MP1100,
plugging it into the electrical outlet and immediately begin flash freezing plasma.

Today, the Company still maintains the premier technology position in the plasma
freezing market segment, with competitors offering primarily 30-year-old blast
freezing (forced air) technology. A direct result of this advantage was the
Company`s success in establishing a significant market position in transfusion
societies and blood banks around the globe. The Company has five models of
freezers which vary primarily by capacity and condenser type. The MP 2000 and
MP 1000/1100 are suited for large laboratories running approximately 750 bags of
plasma per day. The MP 750 and MP 500 are suited for medium sized labs running
250 to 749 bags per day. The Company has three models of thawers. They vary
primarily by capacity: The MT202 thaws two bags simultaneously, and the MT204
and the MT210 four and ten bags respectively. In North America, the four major
manufacturers of plasma freezers are the Company, Revco, Forma Scientific and
Harris.

BioArchive Platform Products

The BioArchive Stem Cell System was the first product developed under the
BioArchive System technology platform. In collaboration with The NYBC, the
Company developed a disposable blood processing bag set that provides a sterile
method for collecting, concentrating and cryopreserving stem and progenitor cells
contained in PCB. These life giving stem and progenitor cells are targeted for
therapeutic use in patients who suffer from malignancies and genetic diseases of
the blood and immune system such as leukemia, lymphomas, diverse inherited
anemias, immunodeficiencies, acquired a plastic anemia and hypoproliferative
disorders.

The BioArchive Stem Cell System features a robotic cryogenic device that
automatically freezes, archives and manages an inventory of up to 3,626 PCB units
of stem and progenitor cells for transplant. The proprietary device also controls and
records the freezing profile of each PCB donation in nitrogen vapor, after which the
PCB unit is robotically transferred to a specified indexed location in liquid nitrogen.
The BioArchive System tracks the storage address of each PCB stem cell unit and
assures that only the specifically chosen, HLA matched PCB unit is retrieved when
selected for a human transplant recipient without exposing the other archived
samples to detrimental warming effects. The PCB stem and progenitor cell
donations are collected, processed, cryopreserved and transfused utilizing three
proprietary sterile disposable bag sets developed jointly by NYBC and the
Company and licensed to Medsep Corporation, a Division of Pall Corp., for
manufacturing and distribution in North America & Europe. The Company
re-acquired the rights to distribute the bag sets under its own name throughout the
rest of the world, except Japan.

In addition, the Company manufactures and sells three additional disposables
(canisters, canister sleeve, and overwrap bag) for the protection of the PCB units
during inter-laboratory transfers and shipment to the transplant centers which the
Company believes will provide an ongoing revenue stream.

The CryoSeal Platform products provide a superior and safer approach to producing
therapeutic doses of these proteins, enzymes and growth factors. Each CryoSeal
System is a micro-manufacturing platform which harvests and concentrates these
therapeutic blood components from the patient`s own blood, or in the case of such
medical conditions as hemophilia, from a directed donor.

[brixlegg]

Ist es sinnvoll solche Aktien an der Nasdaq zu kaufen? Woher kommt die unterschiedliche - teilweise erheblich - Notierung an den verschiedenen Börsen bei ein und derselben Aktie? Ist es da vernünftig die günstigste Variante zu ordern?

Danke

[Stock@dvisor]

Falls der deutsche Kurs erheblich über dem US-Kurs liegt ist es natürlich günstiger an der NASDAQ zu ordern - es sein denn, man erwartet, daß der Eröffnungskurs in den USA noch höher ist. Das kann z.B. bei einer nachbörslichen Hammermeldung durchaus der Fall sein.
Zu berücksichtigen sind auch noch die höheren Transaktionskosten (sprich Gebühren) beim US-Kauf u. die Liquidität des Marktes.

[Stock@dvisor]

Stem Cell Viability Study Presented by THERMOGENESIS CORP
B: Stem Cell Viability Study Presented by THERMOGENESIS CORP. At FDA/NHLBI Stem
Cell Conference; Studies Contribute to Growing Body of Scientific Knowledge On
Stem Cells

RANCHO CORDOVA, Calif., Aug 24, 2000 (BW HealthWire) -- THERMOGENESIS CORP.
(Nasdaq:KOOL) announced that preliminary results, presented by Phil Coelho,
Chairman & CEO of THERMOGENESIS CORP., suggest that cell viability of stem cells
may be adversely affected by stresses that develop during exposure to Transient
Warming Events (TWE). The results were announced at the Unrelated Allogeneic
Cord Blood Banking and Transplant Forum held by FDA/NHLBI in Bethesda, MD on
August 14 & 15, 2000 and The Fourth International Symposium on Hematopoietic
Stem Cell Transplantation Conference in Tokyo, Japan on July 6, 2000.

TWEs may occur as many as 20 to 30 times prior to transplant when stem cell
units are prepared utilizing conventional cryogenic processing equipment. With
conventional processing equipment, the stem cell units are exposed to the
ambient air as they are transferred from the controlled-rate freezer to a
quarantine freezer, from the quarantine to the storage freezer, during storage
as different units stored in the same rack are removed, when removed from
storage and transferred to a cryo shipper, and at least once more when the unit
is placed in the storage dewar at the transplant center.

Tests carried out at the New York Blood Center`s Placental Blood Program
indicated that losses of up to 20% of viable colony forming cells (CFU-C) may
occur with only five TWEs in which the temperature of the frozen graft rises to
-80 degrees C and losses of up to 50% if the frozen graft rises to -40 degrees
C.

James Godsey, Ph.D., President & COO of THERMOGENESIS CORP. noted that ".... The
BioArchive System, which was designed by THERMOGENESIS CORP. to reduce the
incidence and severity of TWEs by more than 90%, is demonstrably the
international standard for collecting, processing, and archiving cryopreserved
hematopoietic stem cells sourced from placental/cord blood (PCB)." PCB stem
cells are used to reconstitute the hematopoietic and immune systems of patients
who have undergone high-dose chemotherapy and radiation to combat diseases such
as leukemias, lymphomas, diverse inherited anemias such as sickle cell anemia
and thalassemia and other genetic diseases. BioArchive systems are now in use by
the major cord blood banks in U.S.A., Germany, Finland, Spain, England, Belgium,
Japan, China, Taiwan and Vietnam.

About the BioArchive System

The BioArchive System uses THERMOGENESIS CORP.`s proprietary computer-driven
liquid nitrogen robotic system to cryopreserve and archive up to 3,626 25ml
units of PCB stem cells that have been collected and preserved in proprietary
sterile plastic bag sets. The BioArchive System tracks identification and
location for each unit and performs robotic retrieval of each unique
tissue-typed unit for use. The BioArchive System operates to freeze, place and
retrieve samples without exposing other archived samples to detrimental
temperature changes.

The BioArchive System is a Class II exempt blood component freezer, and has
initially been distributed in the U.S. only to IND sites which have received FDA
approvals for use with stem cell storage for transplant into unrelated patients.
The BioArchive System has potential applications involving archiving, storing,
managing and retrieving other kinds of biological specimens, that may include
peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs,
heart valves, corneas, virus samples, biopsy samples and other blood, tissue and
saliva samples. THERMOGENESIS CORP. BioArchive system is currently intended for
preservation of blood components and blood products and would require FDA 510(k)
clearance for some additional claims. Use of the BioArchive System in the above
applications may be subject to certain regulations.

About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and
distributing equipment to collect, cryopreserve and archive highly sensitive
blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.

CONTACT: THERMOGENESIS CORP.
James H. Godsey, 916/858-5100
[e-mail]
www.thermogenesis.com

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

[docHollywood]

Hier einige News aus USA

Bye,

DC


Last paragraph is most interesting.

<<Thermogenesis Up 24%; Positive Comments In Europe Cited

DJ Thermogenesis Up 24%; Positive Comments In Europe Cited[KOOL.O] DJ Thermogenesis Up -2: Company Can`t Explain Rise [KOOL.O]

By Miatta V. David Of DOW JONES NEWSWIRES

NEW YORK (Dow Jones)--Shares of Thermogenesis Corp. (KOOL) were recently up 23.3% as Wall Street speculated that positive comments made in Europe may be boosting the stock. In chat rooms on various message boards Tuesday, market watchers cited a biotech specialist who talked about the stock Monday on European station NTV. According to the chat rooms, the specialist said he prefers Thermogenesis compared with biotech company Amgen Inc. (AMGN) and Immunex Corp. (IMNX). The specialist was not identified.

Thermogenesis` President and Chief Operating Officer James Godsey said the company had not previously heard of the positive comments and added that the company had no idea what was moving the stock. Godsey did mention that Chairman and Chief Executive Phil Coelho recently visited Europe.

Shares of the Rancho Cordova, Calif., company were up 59 cents, or 22.1%, at $3.28 on volume of 1.5 million shares, compared with daily average volume of 116,700 shares.

In May, Thermogenesis reported a loss of 6 cents for the fiscal third quarter ended March 31. Godsey said the company, which designs thermodynamic medical devices that process blood and blood substances, is expecting to report its fourth quarter by the end of September.

Profitability is expected in fiscal 2002, Godsey said.

-Miatta V. David, Dow Jones Newswires; 201-938-5175
(END) Dow Jones Newswires >>